To include your compound in the COVID-19 Resource Center, submit it here.

Selinexor: Preliminary Phase I/II data

Preliminary data from 10 evaluable patients with relapsed or refractory MM who previously received >=2 therapies including Revlimid

Read the full 184 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE